Recent Updates — LQDA
Liquidia Corporation and its subsidiary entered into a global settlement agreement with United Therapeutics to resolve all pending patent infringement, trade secret, breach of contract, and antitrust litigations. Under the terms, Liquidia will make a net payment of $175 million within 30 days and pay an additional $145.4 million in two installments by April 2027. The company also paid $60.3 million to settle interests held by Sandoz, Henderson SPV, and PBM RG Holdings regarding the antitrust proceedings. In exchange for these payments, Liquidia will remove the PH-ILD indication from its YUTREPIA label and cease promotion for that use, while retaining rights to market YUTREPIA for pulmonary arterial hypertension (PAH). The settlement includes mutual releases of claims and dismissals with prejudice. Liquidia reported preliminary Q3 2026 YUTREPIA net sales of $222.7 million and cash holdings of $396.1 million as of September 30, 2026. Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products for respiratory and vascular diseases using its proprietary PRINT technology.
Liquidia Corporation reported a partial adverse ruling in Hatch-Waxman litigation filed by United Therapeutics Corporation regarding U.S. Patent No. 11,826,327 and its lead product YUTREPIA (treprostinil). The court found claims 1 and 14 valid and infringed, covering the treatment of pulmonary hypertension with interstitial lung disease (PH-ILD), while other asserted claims were deemed invalid. Liquidia intends to appeal and plans to submit a New Drug Application supplement to remove the PH-ILD indication from YUTREPIA's label. United Therapeutics has requested injunctive relief that could restrict product availability, though financial exposure remains unestimable due to ongoing proceedings. This company operates in the biopharmaceutical industry, developing therapies for respiratory and vascular diseases using proprietary PRINT technology.
Liquidia Corporation announced that the U.S. Food and Drug Administration granted Fast Track Designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). This designation facilitates expedited development and review due to the serious nature of the condition and lack of approved therapies, potentially enabling rolling New Drug Application review. The company plans to initiate the RE-WARM Phase 2a dose-finding study in October 2026 for approximately 75 adults with SSc-RP. Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products for respiratory and vascular diseases using its proprietary PRINT technology.
Liquidia Corporation reported second quarter 2026 financial results on August 12, 2026. Net product sales for YUTREPIA reached approximately $170.4 million, a 31% increase from the first quarter of 2026. The company recorded net income of $74.7 million and adjusted EBITDA of $96.3 million, marking its fourth consecutive quarter of increasing profitability. Cash and cash equivalents totaled $284.2 million as of June 30, 2026. Since launching in June 2025, YUTREPIA has generated approximately 5,900 unique patient prescriptions and treated more than 5,000 patients. Liquidia Corporation is a biopharmaceutical company developing therapies for respiratory and vascular diseases using its proprietary PRINT technology.
Liquidia Corporation announced that it will be added to the S&P SmallCap 600 Index, effective prior to the opening of trading on June 22, 2026.